EU Softens On Tallow Product Imports

8 September 1997

Possibly as a result of pressure from the USA, a European Union panel ofexperts last week recommended a relaxation on the rules for import of tallow products, many of which are used in making pharmaceuticals (Marketletter August 18). The USA claimed that an EU ban on imports of animal products due to the outbreak of Creutztfeld-Jacob disease as a result of bovine spongiform encephalopathy in cattle could threaten $100 million worth of US tallow exports.

The committee's opinion, that tallow-derived products could be seen as safe for human use if "the appropriate, validated and scientifically most up-to-date methods" are used in their production, is likely to be become a proposal to EU commissioners.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight